An Acquired Factor VIII Inhibitor in a Patient with HIV and HCV: A Case Presentation and Literature Review

Table 2

Laboratory values and treatment regimen used during patient’s hospital course.

	Admission	Day 7	Day 21	Day 35
Hemoglobin (g/dL)	7.2	8.6	10.0	11.4
Hematocrit	22.3	26.3	31.6	37.9
Platelet count (/uL)	200∗10^3	204∗10^3	130∗10^3	160∗10^3
PTT (s)	65.6	62.4	63.5	44.3
Factor VIII activity (%)	<0.1	3	14	23
Total pRBCs used	—	15	25	30
Treatment regimen	—	(1) Solumedrol 80 mg IV q 8 hrs; (2) Cyclophosphamide 50 mg PO daily; (3) Recombinant coagulation factor VIIa 2000 mcg IV BID	(1) Solumedrol 80 mg IV q 8 hrs; (2) Cyclophosphamide 50 mg PO daily; (3) Recombinant coagulation factor VIIa 1000 mcg IV TID	(1) Solumedrol 80 mg IV q 8 hrs; (2) Cyclophosphamide 50 mg PO daily